Pages without language links

Jump to navigation Jump to search

The following pages do not link to other language versions.

Showing below up to 50 results in range #4,451 to #4,500.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  2. Section 3.3.2. Hybridization-Based Enrichment (from DOI: 10.3390/v12020211)
  3. Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265)
  4. Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  5. Section 3.3.3. Target Amplification (from DOI: 10.3390/v12020211)
  6. Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  7. Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  8. Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  9. Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  10. Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5)
  11. Section 3.3. Methods for Improving Sequencing Output (from DOI: 10.3390/v12020211)
  12. Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265)
  13. Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  14. Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265)
  15. Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265)
  16. Section 3.4. Whole Viral Genome Sequencing (from DOI: 10.3390/v12020211)
  17. Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265)
  18. Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265)
  19. Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
  20. Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265)
  21. Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
  22. Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)
  23. Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)
  24. Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265)
  25. Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265)
  26. Section 3.5. Methods of Sequencing Data Analysis (from DOI: 10.3390/v12020211)
  27. Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265)
  28. Section 3. Studying Viral Pathogens with High Throughput Sequencing (HTS) (from DOI: 10.3390/v12020211)
  29. Section 3: COVID-19: Neuro-invasive potential of SARS-nCoV-2 as cause of delirium (from DOI: 10.1186/s13054-020-02882-x)
  30. Section 3: Cardiovascular Comorbidities and COVID-19 Outcomes (from DOI: 10.1007/s11886-020-01293-2)
  31. Section 3: Conclusions and priorities for future research (from DOI: 10.1016/j.jcv.2020.104372)
  32. Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265)
  33. Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5)
  34. Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653)
  35. Section 3: Mechanism of SARS-CoV-2 invasion into host cells (from DOI: 10.1016/j.clim.2020.108427)
  36. Section 3: Results (from DOI:10.14218/ERHM.2020.00023)
  37. Section 3: Results (from DOI: 10.1016/j.adro.2020.04.015)
  38. Section 3: The Role of Host Immune Response (from DOI: 10.1007/s11886-020-01292-3)
  39. Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5)
  40. Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5)
  41. Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5)
  42. Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5)
  43. Section 4. Long Read Sequencing (from DOI: 10.3390/v12020211)
  44. Section 4: COVID-19: ICU delirium management:potential problems and solutions (from DOI: 10.1186/s13054-020-02882-x)
  45. Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653)
  46. Section 4: Conclusion (from DOI: 10.1007/s11886-020-01293-2)
  47. Section 4: Discussion (from DOI:10.14218/ERHM.2020.00023)
  48. Section 4: Discussion (from DOI: 10.1016/j.adro.2020.04.015)
  49. Section 4: Host response to SARS-CoV-2 (from DOI: 10.1016/j.clim.2020.108427)
  50. Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:WithoutInterwiki"